XRTX Stock Chart & Stats
$2.02
>-$0.01(-0.25%)
At close: 4:00 PM EDT
$2.02
>-$0.01(-0.25%)
Day’s Range― - ―
52-Week Range$1.73 - $7.05
Previous Close$2.07
Volume18.14K
Average Volume (3M)3.79M
Market Cap
$3.68M
Enterprise Value$3.22
Total Cash (Recent Filing)$250.45K
Total Debt (Recent Filing)$15.07K
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,816,565
10 Day Avg. Volume11,302,330
30 Day Avg. Volume3,791,937
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.26
Revenue Forecast (FY)$2.33M
Bulls Say, Bears Say
Bulls Say
Very Low LeverageExtremely low debt reduces financial risk and interest burdens, giving management flexibility to prioritize R&D spending and clinical milestones. For a clinical-stage biotech, low leverage preserves optionality to pursue trials or partnerships without immediate repayment pressure, aiding multi‑month planning.
Improving Loss TrendsSubstantial reduction in operating losses signals improved cost control or streamlined development spending. Sustained narrowing of losses strengthens the company's operational sustainability, reduces future cash needs if continued, and makes funding rounds or partnerships more feasible over a 2–6 month horizon.
Focused Clinical-stage PipelineA concentrated strategy on kidney and metabolic small-molecule programs provides clear R&D focus, enabling efficient resource allocation and deeper domain expertise. That specialization improves the odds of meaningful clinical progress or attractive partnering/licensing opportunities over the medium term.
Bears Say
No Recurring RevenueAbsence of product revenue means the business lacks an internal cash-generation engine and remains dependent on external financing or milestone payments. Over months this elevates execution risk: trial setbacks or funding market strains can rapidly curtail operations absent clear commercialization pathways.
Persistent Negative Cash FlowConsistent negative operating and free cash flow erodes cash reserves and shortens runway, forcing frequent capital raises. This structural cash burn pattern increases dilution risk, constrains strategic options, and makes sustaining multi‑period clinical programs contingent on external funding availability.
Shrinking Equity Base And Funding RelianceA materially smaller equity cushion and historical reliance on issuing shares for funding weakens balance-sheet resilience. Continued dilution risk reduces stakeholder buffers against trial delays or costs, and raises the probability of dilutive financings that can affect long‑term capital structure and strategic flexibility.
XORTX Therapeutics Inc News
XRTX FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was $1.73 and its highest was $7.05 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is $3.68M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 11 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -$0.58 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc pays a Quarterly dividend of $0.075 which represents an annual dividend yield of N/A. See more information on XORTX Therapeutics Inc dividends here
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,816,565 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.686%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in XRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
Based in Vancouver, Canada, XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering and bringing to market treatments for a variety of conditions, including progressive kidney disorders, diabetes, insulin resistance, metabolic syndrome, and infections. The company's pipeline includes XRx-008, a late-stage clinical program addressing autosomal dominant polycystic kidney disease; XRx-101, an agent designed to reduce uric acid levels in COVID-19 patients to prevent acute kidney injury and its associated health issues; and XRx-221, a series of xanthine oxidase inhibitor candidates aimed at treating diabetic nephropathy. Furthermore, XORTX Therapeutics collaborates with the Icahn School of Medicine to research the occurrence of acute kidney injury and elevated uric acid in patients hospitalized with COVID-19.
Technical Analysis
Ownership Overview
0.02%
Insiders
0.83% Other Institutional Investors
99.16% Public Companies and
Individual Investors